Endometrial cancer treatment approved in Canada
As an anti-PD-1 treatment for relapsed or advanced endometrial cancer approved in Canada, JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) or high microsatellite instability ( MSI-H) recurrent or advanced endometrial cancer, which has progressed during or after previous treatment with a diet containing platinum.
“Canadian women with recurrent endometrial cancer or advanced disease that has progressed during or after chemotherapy currently have few treatment options and face a poor prognosis,” said Marni Freeman, National Medical Director at GSK Canada. âThis critical approval has the potential to significantly improve the treatment landscape for these women and demonstrates GSK’s continued commitment to address an unmet need in patients with gynecologic cancer.
âWomen with endometrial cancer have few treatment options. At the Society of Gynecologic Oncology of Canada (GOC), we welcome any approval that paves the way for women with endometrial cancer to access immunotherapy as part of their standard treatment options, âsaid said Dr. Helen MacKay, President, The Society of Gynecologic Oncology. from Canada and Head of the Medical Oncology and Hematology Division, Sunnybrook Odette Cancer Center.
Endometrial cancer is the most common gynecologic cancer in Canada. The disease is found in the inner lining of the uterus, known as the endometrium, and accounts for 95% of all uterine cancers. An estimated 7,600 Canadian women will be diagnosed with endometrial cancer and 1,235 will die from it in 2021.
Treatment options are limited for women whose disease progresses during or after first-line treatment. About 25% of women with endometrial cancer will be diagnosed with advanced disease and 20% will have disease recurrence. 5-year overall survival is estimated at 83%, but it is less than 20% for people with metastatic disease, so research and availability of new treatments is of the utmost importance.